COVID-19 vaccines in patients with hematologic malignancy: summary of studies evaluating the efficacy of COVID-19 vaccines in >10 patients with hematologic malignancy
| Reference . | Patient population . | Vaccine type/ vaccine regimen . | Endpoint . | Results . |
|---|---|---|---|---|
| 65 | 200 cancer patients | FDA-approved COVID-19 vaccines | Seroconversion | |
| Overall | 94% | |||
| Type of vaccine | ||||
| BNT162b2 | 95% | |||
| mRNA-1273 | 94% | |||
| Ad26.COV2.S | 85% | |||
| Type of cancer therapy | ||||
| Anti-CD20 | 70% | |||
| Stem cell transplant | 73% | |||
| CAR-T cell | 0 | |||
| Hormonal | 100% | |||
| Immune checkpoint inhibitor | 97% | |||
| 71 | 80 HM patients | Double-dose BNT162b2 | Seroconversion | |
| Type of treatment | ||||
| CAR-T cell | 36% | |||
| Allogeneic stem cell transplant | 75% | |||
| ELISpot positivity | ||||
| Type of treatment | ||||
| CAR-T cell | 50% | |||
| Allogeneic stem cell transplant | 19% | |||
| 72 | 32 HM patients | Double-dose BNT162b2 and Ad26-COV2.S boost | Seroconversion | |
| Overall | 31% | |||
| Type of HM | ||||
| CLL or lymphoma | 16.7% | |||
| 73 | 270 HM patients | Double-dose mRNA-1273 | Seroconversion | |
| Overall | 76.3% | |||
| Treatment status | ||||
| Off-therapy >6 mo | 91.7% | |||
| On-therapy/off-therapy <6 mo | 63.7% | |||
| Treatment-naïve | 96.7% | |||
| Type of treatment | ||||
| BTK | 86.2% | |||
| IMIDs | 100% | |||
| Anti-CD20 alone | 18.5% | |||
| CHI ±anti-CD20 | 27.8% | |||
| Cellular response | ||||
| Overall | 79% | |||
| Treatment status | ||||
| Off-therapy >6 mo | 85.7% | |||
| On-therapy/off-therapy < 6 mo | 78% | |||
| Treatment-naïve | 86.7% | |||
| Type of treatment | ||||
| BTK | 81.5% | |||
| IMIDs | 92.3% | |||
| Anti-CD20 alone | 80% | |||
| CHI ±anti-CD20 | 50% | |||
| 69 | 49 HM patients | Booster BNT162b2 or mRNA-1273 | Seroconversion | |
| Overall | 65% | |||
| Treatment status | ||||
| Off-treatment >24 mo | 92.9% | |||
| Completed anti-CD20 | 42.9% | |||
| Prior anti-CD20 <7 mo | 71.4% | |||
| BTK | 61.1% | |||
| 81 | 100 HM patients | Double-dose BNT162b2 or mRNA-1273 | Seroconversion | |
| Overall | 49% | |||
| Treatment status | ||||
| Anti-CD20 <12 mo prior | 26% | |||
| After booster dose | 41.7% | |||
| 75 | 160 HM patients | FDA-approved COVID-19 vaccines | Seroconversion Overall | 39.4% |
| Treatment status | ||||
| B-cell/plasma cell-depleting mAb | 29% | |||
| Active disease | 27% | |||
| In remission | 49% | |||
| Watch & wait | 67% | |||
| CHI >12 mo prior | 69% | |||
| CHI < 12 mo prior | 24% | |||
| 70 | 239 HM patients | Double-dose BNT162b2 | Seroconversion | |
| Overall | 47% | |||
| Cellular response | Cellular response | |||
| Overall | 53% | |||
| 83 | 123 HM patients | BNT162b2 | Seroconversion | |
| 1 dose | 43.4% | |||
| Double-dose | 71.4% | |||
| 76 | 58 HM patients | Single dose BNT162b2 or AZD1222 | Neutralizing antibodies | |
| ≥30% | 14% | |||
| ≥50% | 5% | |||
| 77 | 102 HM patients | Single dose BNT162b2 or mRNA-1273 | Seroconversion | |
| Overall | 61.8% | |||
| Treatment | ||||
| Anti-CD20 <12 mo | 5.9% | |||
| Anti-CD20 >12 mo | 63.6% | |||
| 66 | 857 HM patients | Single-dose and double-dose BNT162b2 | Median anti-S IgG level (AU/mL) | |
| Overall | 6 961 | |||
| Age | ||||
| >60 y | 1 140 | |||
| Treatment | ||||
| Treatment-naïve | 5 761 | |||
| Ruxolitinib | 10 | |||
| BTKi | 0 | |||
| Anti-CD20 | 17 | |||
| Hydroxycarbamide | 1 825 | |||
| IMID | 679 | |||
| TKIs | 10 537 | |||
| Anagrelide/interferon | 6 927 | |||
| Auto SCT | 6 203 | |||
| Allogeneic SCT | 6 304 | |||
| 78 | 315 HM patients | Double-dose BNT162b2 | Seroconversion | |
| Overall | 75% | |||
| HM subtype | ||||
| Aggressive NHL | 71% | |||
| Indolent NHL | 60% | |||
| Hodgkin lymphoma | 94% | |||
| Multiple myeloma | 76% | |||
| CLL | 47% | |||
| Acute leukemia | 80% | |||
| MDS | 94% | |||
| MPN | 84% | |||
| CML | 91% | |||
| 82 | 1 445 HM patients | Double-dose BNT162b2 or mRNA-1273 | Seroconversion | |
| Overall | 75% | |||
| HM subtype | ||||
| ALL | 88.2% | |||
| AML | 91.2% | |||
| Burkitt lymphoma | 100% | |||
| CLL | 64.2% | |||
| CML | 97.1% | |||
| Diffuse large B cell lymphoma | 78.8% | |||
| Follicular lymphoma | 77.6% | |||
| Hairy cell leukemia | 100% | |||
| Hodgkin lymphoma | 98.5% | |||
| Mantle cell lymphoma | 44.4% | |||
| Marginal zone lymphoma | 61.8% | |||
| MDS/MPN | 97.1% | |||
| Multiple myeloma | 95.1% | |||
| Primary CNS lymphoma | 50% | |||
| Primary mediastinal large B-NHL | 100% | |||
| Smoldering myeloma | 100% | |||
| T cell lymphoma | 84.6% | |||
| Waldenstrom macroglobulinemia | 74.2% | |||
| 79 | 585 cancer patients | Double-dose BNT162b2 or AZD1222 | Seroconversion | |
| Overall | 78% | |||
| Cancer subtype | ||||
| HM | 59% | |||
| Solid cancer | 85% | |||
| 85 | 132 HM patients | BNT162b2 | Neutralizing SARS-CoV-2 antibodies inhibition titer | |
| Median | 32.5% | |||
| ≥30% | 50.8% | |||
| ≥50% | 43.9% |
| Reference . | Patient population . | Vaccine type/ vaccine regimen . | Endpoint . | Results . |
|---|---|---|---|---|
| 65 | 200 cancer patients | FDA-approved COVID-19 vaccines | Seroconversion | |
| Overall | 94% | |||
| Type of vaccine | ||||
| BNT162b2 | 95% | |||
| mRNA-1273 | 94% | |||
| Ad26.COV2.S | 85% | |||
| Type of cancer therapy | ||||
| Anti-CD20 | 70% | |||
| Stem cell transplant | 73% | |||
| CAR-T cell | 0 | |||
| Hormonal | 100% | |||
| Immune checkpoint inhibitor | 97% | |||
| 71 | 80 HM patients | Double-dose BNT162b2 | Seroconversion | |
| Type of treatment | ||||
| CAR-T cell | 36% | |||
| Allogeneic stem cell transplant | 75% | |||
| ELISpot positivity | ||||
| Type of treatment | ||||
| CAR-T cell | 50% | |||
| Allogeneic stem cell transplant | 19% | |||
| 72 | 32 HM patients | Double-dose BNT162b2 and Ad26-COV2.S boost | Seroconversion | |
| Overall | 31% | |||
| Type of HM | ||||
| CLL or lymphoma | 16.7% | |||
| 73 | 270 HM patients | Double-dose mRNA-1273 | Seroconversion | |
| Overall | 76.3% | |||
| Treatment status | ||||
| Off-therapy >6 mo | 91.7% | |||
| On-therapy/off-therapy <6 mo | 63.7% | |||
| Treatment-naïve | 96.7% | |||
| Type of treatment | ||||
| BTK | 86.2% | |||
| IMIDs | 100% | |||
| Anti-CD20 alone | 18.5% | |||
| CHI ±anti-CD20 | 27.8% | |||
| Cellular response | ||||
| Overall | 79% | |||
| Treatment status | ||||
| Off-therapy >6 mo | 85.7% | |||
| On-therapy/off-therapy < 6 mo | 78% | |||
| Treatment-naïve | 86.7% | |||
| Type of treatment | ||||
| BTK | 81.5% | |||
| IMIDs | 92.3% | |||
| Anti-CD20 alone | 80% | |||
| CHI ±anti-CD20 | 50% | |||
| 69 | 49 HM patients | Booster BNT162b2 or mRNA-1273 | Seroconversion | |
| Overall | 65% | |||
| Treatment status | ||||
| Off-treatment >24 mo | 92.9% | |||
| Completed anti-CD20 | 42.9% | |||
| Prior anti-CD20 <7 mo | 71.4% | |||
| BTK | 61.1% | |||
| 81 | 100 HM patients | Double-dose BNT162b2 or mRNA-1273 | Seroconversion | |
| Overall | 49% | |||
| Treatment status | ||||
| Anti-CD20 <12 mo prior | 26% | |||
| After booster dose | 41.7% | |||
| 75 | 160 HM patients | FDA-approved COVID-19 vaccines | Seroconversion Overall | 39.4% |
| Treatment status | ||||
| B-cell/plasma cell-depleting mAb | 29% | |||
| Active disease | 27% | |||
| In remission | 49% | |||
| Watch & wait | 67% | |||
| CHI >12 mo prior | 69% | |||
| CHI < 12 mo prior | 24% | |||
| 70 | 239 HM patients | Double-dose BNT162b2 | Seroconversion | |
| Overall | 47% | |||
| Cellular response | Cellular response | |||
| Overall | 53% | |||
| 83 | 123 HM patients | BNT162b2 | Seroconversion | |
| 1 dose | 43.4% | |||
| Double-dose | 71.4% | |||
| 76 | 58 HM patients | Single dose BNT162b2 or AZD1222 | Neutralizing antibodies | |
| ≥30% | 14% | |||
| ≥50% | 5% | |||
| 77 | 102 HM patients | Single dose BNT162b2 or mRNA-1273 | Seroconversion | |
| Overall | 61.8% | |||
| Treatment | ||||
| Anti-CD20 <12 mo | 5.9% | |||
| Anti-CD20 >12 mo | 63.6% | |||
| 66 | 857 HM patients | Single-dose and double-dose BNT162b2 | Median anti-S IgG level (AU/mL) | |
| Overall | 6 961 | |||
| Age | ||||
| >60 y | 1 140 | |||
| Treatment | ||||
| Treatment-naïve | 5 761 | |||
| Ruxolitinib | 10 | |||
| BTKi | 0 | |||
| Anti-CD20 | 17 | |||
| Hydroxycarbamide | 1 825 | |||
| IMID | 679 | |||
| TKIs | 10 537 | |||
| Anagrelide/interferon | 6 927 | |||
| Auto SCT | 6 203 | |||
| Allogeneic SCT | 6 304 | |||
| 78 | 315 HM patients | Double-dose BNT162b2 | Seroconversion | |
| Overall | 75% | |||
| HM subtype | ||||
| Aggressive NHL | 71% | |||
| Indolent NHL | 60% | |||
| Hodgkin lymphoma | 94% | |||
| Multiple myeloma | 76% | |||
| CLL | 47% | |||
| Acute leukemia | 80% | |||
| MDS | 94% | |||
| MPN | 84% | |||
| CML | 91% | |||
| 82 | 1 445 HM patients | Double-dose BNT162b2 or mRNA-1273 | Seroconversion | |
| Overall | 75% | |||
| HM subtype | ||||
| ALL | 88.2% | |||
| AML | 91.2% | |||
| Burkitt lymphoma | 100% | |||
| CLL | 64.2% | |||
| CML | 97.1% | |||
| Diffuse large B cell lymphoma | 78.8% | |||
| Follicular lymphoma | 77.6% | |||
| Hairy cell leukemia | 100% | |||
| Hodgkin lymphoma | 98.5% | |||
| Mantle cell lymphoma | 44.4% | |||
| Marginal zone lymphoma | 61.8% | |||
| MDS/MPN | 97.1% | |||
| Multiple myeloma | 95.1% | |||
| Primary CNS lymphoma | 50% | |||
| Primary mediastinal large B-NHL | 100% | |||
| Smoldering myeloma | 100% | |||
| T cell lymphoma | 84.6% | |||
| Waldenstrom macroglobulinemia | 74.2% | |||
| 79 | 585 cancer patients | Double-dose BNT162b2 or AZD1222 | Seroconversion | |
| Overall | 78% | |||
| Cancer subtype | ||||
| HM | 59% | |||
| Solid cancer | 85% | |||
| 85 | 132 HM patients | BNT162b2 | Neutralizing SARS-CoV-2 antibodies inhibition titer | |
| Median | 32.5% | |||
| ≥30% | 50.8% | |||
| ≥50% | 43.9% |
AML, acute myeloid leukemia; CAR-T, chimeric antigen receptor; CHI, chemoimmunotherapy; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; ELISpot, enzyme-linked immunospot; IMIDs, immunomodulatory imide drugs; MDS, myelodysplastic syndrome; MPN, myeloproliferative disease; NHL, non-Hodgkin lymphoma; SCT, stem cell transplantion; TKI, tyrosine kinase inhibitor.